Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-04), Novacyt's 14-Day RSI is 1.23.
The industry rank for Novacyt's 14-Day RSI or its related term are showing as below:
NVYTF's 14-Day RSI is ranked better than 69.47% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 49.185
vs NVYTF: 1.23
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Novacyt 14-Day RSI Related Terms
NVYTF vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Novacyt's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novacyt 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Novacyt's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novacyt (NVYTF) has a 14-Day RSI of 1.23 as of Aug. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Novacyt and its competitors. According to the industry distribution chart, Novacyt ranks #265 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Novacyt's 14-Day RSI too high?
Novacyt's current 14-Day RSI is 1.23. The Medical Devices & Instruments industry median 14-Day RSI is 49.19. Novacyt's value of 1.23 is 97.5% below this industry median. Based on the distribution chart, Novacyt ranks #265 out of 868 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Novacyt has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Novacyt's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Novacyt ranks #265 out of 868 companies for 14-Day RSI. This puts Novacyt in the upper half of its industry. The industry median 14-Day RSI is 49.19. Novacyt's value of 1.23 is 97.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 49.19, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novacyt's current 14-Day RSI of 1.23 is 97.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Novacyt and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 49.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novacyt's current 14-Day RSI is 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novacyt stock overvalued right now?
Novacyt (NVYTF) has a current 14-Day RSI of 1.23. The stock's GF Value™ is $0.72, compared to a current price of $0.48 — trading 33.4% below its estimated fair value. The current 14-Day RSI is 1.23 and 97.5% below the Medical Devices & Instruments industry median of 49.19. Novacyt's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Novacyt (NVYTF), the current 14-Day RSI is 1.23 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novacyt (NVYTF) Overvalued in 2026?
Based on GuruFocus' analysis, Novacyt stock appears to be undervalued.
The current stock price of $0.48 is trading 33.4% below its estimated GF Value™ of $0.72.
Key valuation signals for NVYTF:
14-Day RSI: 1.23
GF Value™: $0.72 vs. price of $0.48 (33.4% below fair value)
Industry Position: 97.5% below the Medical Devices & Instruments median (#265 of 868)
No single metric tells the full story. See the NVYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
33GF Score
Get the complete analysis for NVYTF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVYTF has been successfully added to your 
